|
Canada-0-Insurance företaget Kataloger
|
Företag Nyheter:
- Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes and obesity Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is a daily pill
- Semaglutide Does Not Treat Alzheimer’s. Could It Prevent Dementia?
Semaglutide mildly shifted some CSF AD biomarkers, although the drug is not expected to reduce amyloid Some scientists believe semaglutide could prevent AD or other dementias, if started earlier
- ALZFORUM | NETWORKING FOR A CURE
Neurogenesis is regulated by epigenetic changes In Alzheimer’s disease, these changes inhibit formation of new cells; in superagers, they turn on resilience genes that promote neuron formation
- 301 Moved Permanently
Moved Permanently The document has moved here
- Semaglutide ameliorates Alzheimers disease and restores oxytocin in . . .
Zhang Y, Tang C, He Y, Zhang Y, Li Q, Zhang T, Zhao B, Tong A, Zhong Q, Zhong Z Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP PS1 mice and human brain organoid models
- Therapeutics - ALZFORUM
AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
- New NLRP3 Inhibitor Acts In Brain to Melt Obesity | ALZFORUM
NLRP3 inhibitor must pass into brain to effect weight loss in obese mice The inhibitor calms microgliosis in the hypothalamus, raising hopes for such effects in other brain areas TN-783 complemented semaglutide, promoting further weight loss after the GLP-1 mimetic had plateaued
- Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction . . .
Rubin R Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? JAMA 2024 May 14;331 (18):1519-1521 PubMed
|
|